We invest across the global healthcare industry and investments are made across the capital structure in one of two complementary strategies: private equity and public equity.
Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation. The firm was founded in 2013 by Frank Yu, Chief Executive Officer and Chief Investment Officer, and manages assets from offices in New York and Hong Kong.
Since our establishment, we have been the lead or co-lead on over $6 billion of transactions across healthcare subsectors. Our mission is to generate superior risk-adjusted returns for investors while seeking to address unmet medical needs. We aim to achieve this by blending deep scientific and clinical research with proven M&A and capital markets expertise.
Bridging the Gap Between Private and Public Markets.
Private Equity
Our initial platform established in 2013.
Public Equity
A long-biased strategy launched in 2018.
We seek to deliver superior returns through our understanding of value across private and public markets.
Global Knowledge. Local Talent. Cross Market Expertise.
We aim to reap synergies across our private equity and public equity platforms, by attempting to leverage the strength of our global franchise to source and secure opportunities for our investors in high-impact life science innovation.
Leadership
Frank Yu
Founder, Co-Chief Executive Officer, Co-Chief Investment Officer
Frank Yu founded Ally Bridge Group in 2013 and is Co-Chief Executive Officer and Co-Chief Investment Officer. In this capacity, Frank is responsible for setting firmwide strategic initiatives and leading investment objectives across high-impact life science transactions in private and public markets globally. Before founding Ally Bridge Group’s predecessor company in 2009, Themes Investment Partners, Frank was a Managing Director and Head of China Investments at Sculptor Capital Management (formerly Och-Ziff Capital Management). Before that, Frank spent nearly a decade at Goldman Sachs in Hong Kong, initially in Credit Risk Management and then in the Investment Banking Division as a Managing Director. Frank began his career as a Research Associate at Moody’s in New York before joining Credit Suisse as a Risk Officer in London and then Hong Kong. Frank holds a BA in Economics and Applied Mathematics from Queens College of the City University of New York.
Frank currently serves on the Board of Trustees to the Solomon R. Guggenheim Foundation and on the Advisory Board to the Hong Kong Life Sciences Society.
Simos Simeonidis, PhD
Co-Chief Executive Officer, Co-Chief Investment Officer
Simos Simeonidis, PhD joined Ally Bridge Group in 2022 and is Co-Chief Executive Officer and Co-Chief Investment Officer. He is also Portfolio Manager for Ally Bridge Group’s public equity strategy. Most recently, Simos was Partner, Senior Managing Director, Co-Head of Research and Portfolio Manager at Sarissa Capital Management, an investment manager focused on shareholder activism in healthcare. Before that, Simos was Managing Director/Senior Biotechnology Analyst at Royal Bank of Canada and spent over a decade covering biopharmaceuticals at several investment banks, including Cowen and Morgan Stanley. Simos began his industry career in Business Development at Novartis. Before moving to industry, Simos was a faculty member at Harvard Medical School. Simos holds a BS in Biology from Loyola University, MA, MPhil and PhD degrees in Molecular Biology from Columbia University, completed his postdoctoral fellowship at Harvard Medical School, and an MBA in Healthcare Management from the Wharton School.
Simos currently serves on the board of Fondation Sante, supporting biomedical research in Greece.
Private Equity
Investment Team
Charles Chon, CFA
Managing Director
Charles Chon joined Ally Bridge Group in 2013 and is a Managing Director for the private equity strategy focused on investments in medical technology. Before joining Ally Bridge Group, Charles was Sector Head for U.S. medical devices research at Stifel Nicolaus, and previously a Senior Equity Research Analyst at Goldman Sachs. Charles began his career at ABN AMRO before moving to Fred Alger Management. Charles holds a BA in Chemistry from Amherst College where he graduated cum laude and received an MBA in Healthcare Management from Boston University. He is a CFA charterholder.
Kevin Reilly
Managing Director
Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Special Investments, for the private equity strategy focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel Nicolaus. Kevin holds a BS in Finance and Information Systems from the University of Maryland.
Andrew Pang
Managing Director
Andrew Pang is a Managing Director for Ally Bridge Group’s private equity strategy, leading the firm’s digital health effort and focusing on deal execution in medical devices. Before joining Ally Bridge Group’s predecessor company in 2010, Themes Investment Partners, Andrew worked at InterLeader, a family office in Hong Kong, where he focused on private equity transactions. Andrew began his career at Bank of America in London in the European leveraged buyout group. Andrew holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honors.
Reese Yeh
Managing Director
Reese Yeh is a Managing Director for Ally Bridge Group’s private equity strategy focusing on deal execution of transactions and investments in biopharmaceuticals. Before joining Ally Bridge Group’s predecessor company in 2012, Themes Investment Partners, Reese worked at Morgan Stanley where she focused on private equity transactions across Greater China and the Southeast Asia region. Reese holds a BBA in Finance from National Taiwan University.
Andrew Lam, PharmD
Principal
Andrew Lam joined Ally Bridge Group in 2021 and is a Principal, Special Investments, for the private equity strategy focused on therapeutics. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Before that, Andrew was a Vice President in the Healthcare Investment Banking Group at Jefferies and an equity Research Associate at BMO Capital and Canaccord Genuity. Andrew began his career several biotechnology companies, including Celgene and Shire. Andrew holds a PharmD from Long Island University and received an MBA from Drexel University.
Tinnie Chau, CFA
Vice President
Tinnie Chau joined Ally Bridge Group in 2015 and is a Vice President for the private equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Tinnie was a Manager in the Corporate Finance department of PricewaterhouseCoopers, providing advisory services on M&A transactions across industries with a focus in the healthcare sector. Tinnie holds a BA and MA in Biological Natural Sciences from the University of Cambridge. She is a CFA charterholder.
David Fang, MD, CFA
Vice President
David Fang joined Ally Bridge Group in 2022 and is a Vice President, Special Investments, for the private equity strategy focused on therapeutics. Before joining Ally Bridge Group, David was an Associate Director, Strategy & Business Development, at Alexion Pharmaceuticals and a member of the AstraZeneca Corporate Ventures team (secondment). David began his career as an equity research associate covering biotechnology at SunTrust Robinson Humphrey. David holds a BS in Electrical Engineering from Northwestern University and he received an MD from the University of Michigan Medical School. He is a CFA charterholder.
Sebastian Paquette, CFA
Vice President
Sebastian Paquette joined Ally Bridge Group in 2021 and is a Vice President for the private equity strategy focused on investments in digital health and medical devices. Before joining Ally Bridge Group, Sebastian was the Director of Healthcare at Solid Rock Group. Before that, Sebastian founded two healthcare companies focused on surgeon practice restructuring and medical device supply chain efficiency. Sebastian began his career at Goldman Sachs as a Research Analyst. Sebastian holds a BA in Psychology from Boston College. He is a CFA charterholder.
Keith Lee
Associate
Keith Lee joined Ally Bridge Group in 2022 and is an Associate for the private equity strategy. Before joining Ally Bridge Group, Keith was an Associate in the Healthcare Investment Banking Group at Jefferies. Before that, Keith worked in investment banking at Wedbush PacGrow and Ocean Park Advisors covering biopharma and renewable energy, respectively. Keith began his career as an Analyst in the Investment Consulting Division of Wilshire Associates. Keith holds a BA in Economics and minor in Accounting from the University of California, San Diego where he graduated magna cum laude.
Jonathan Wang, CFA, CPA
Associate
Jonathan Wang joined Ally Bridge Group in 2021 and is an Associate for the private equity strategy. Before joining Ally Bridge Group, Jonathan worked as an Investment Manager at Navis Capital Partners. Before that, Jonathan worked in PricewaterhouseCoopers’ Transaction Services division. Jonathan holds an MPhil in Biochemistry from the University of Hong Kong and a BS in Applied Biology and Biotechnology from the Hong Kong Polytechnic University. He is a CFA charterholder and Certified Public Accountant.
Debra Jiang
Analyst
Debra Jiang joined Ally Bridge Group in 2021 and is an Analyst for the private equity strategy. Before joining Ally Bridge Group, Debra was an Analyst in the Healthcare Investment Banking Group at Morgan Stanley. Debra holds a BS in Statistics from Duke University.
Business Team
Flora Cai
Head of Compliance
Flora Cai joined Ally Bridge Group in 2021 and is Head of Compliance for the private equity strategy. Before joining Ally Bridge Group, Flora was a Principal of Legal and Compliance at CPE Group where she was responsible for overseeing the compliance function for the entire team, responsible for both USD and RMB denominated private equity and hedge funds. Before that, Flora was a Director and Head of Legal and Compliance at UBS SDIC Asset Management. Flora began her career at Deacons. Flora holds an LLB from Shantou University and an LLM from the University of Hong Kong.
Stella Chan
Executive Assistant
Stella Chan joined Ally Bridge Group in 2021 and is an Executive Assistant. Before joining Ally Bridge Group, Stella was an Executive Assistant to the North Asia Chairman at Warburg Pincus for 12 years. Stella has more than 20 years of secretarial experience.
Kelly Cheng, CPA
Vice President
Kelly Cheng joined Ally Bridge Group in 2021 and is a Vice President on the finance team. In this capacity, Kelly is responsible for corporate and general partner-related finance and operations. Before joining Ally Bridge Group, Kelly was a senior member of the Corporate Accounting team at Citadel. Before that, Kelly worked at Bank of America as a legal entity controller. Kelly began her career at PricewaterhouseCoopers and then Deloitte. Kelly holds BCom in Accounting and Economics from the University of New South Wales. She is a Certified Public Accountant.
Amy Herrup, CFA
Head of Business Development and Investor Relations
Amy Herrup joined Ally Bridge Group in 2021 and is Head of Business Development and Investor Relations. Before joining Ally Bridge Group, Amy was a Director in Client Solutions at Capstone Investment Advisors, LLC. Before that, Amy managed investor relations at Varadero Capital, L.P. Amy began her career at Goldman Sachs in the Securities Division. Amy holds a BA in Economics and Mathematical Methods in the Social Sciences from Northwestern University. She is a CFA charterholder.
Sharon Lam, CPA
Finance Manager
Sharon Lam joined Ally Bridge Group in 2021 and is a Finance Manager for the private equity strategy. Before joining Ally Bridge Group, Sharon was a Finance Manager at Welkin Capital, an Asia-focused growth equity investment firm. Sharon holds a BCom in Accounting from Macquarie University in Australia. She is a Certified Public Accountant.
Autumn Langholz
Executive Assistant
Autumn Langholz joined Ally Bridge Group in 2022 and is an Executive Assistant. Before joining Ally Bridge Group, Autumn was an Executive Assistant at Sensiva Health, Target Corporation and Waterstone Capital Management. Autumn has more than 15 years of experience as an Executive Assistant.
Amy Lau
Executive Assistant
Amy Lau joined Ally Bridge Group in 2021 and is an Executive Assistant. Before joining Ally Bridge Group, Amy was an Executive Assistant at CPE Group, UBS and Citigroup. Amy has more than 15 years of secretarial experience.
Boaz Ma, CPA
Finance Manager
Boaz Ma joined Ally Bridge Group in 2021 and is a Finance Manager for the private equity strategy. Before joining Ally Bridge Group, Boaz was an auditor at PricewaterhouseCoopers where he specialized in private equity, venture capitalist and real estate funds. Boaz holds a BBA in Accounting and Finance from the University of Hong Kong. He is a Certified Public Accountant.
Bowie Pang
Financial Controller
Bowie Pang joined Ally Bridge Group in 2021 and is a Financial Controller for the private equity strategy. Before joining Ally Bridge Group, Bowie was the Financial Controller at Fulcrum Global. Before that, Bowie worked in the private equity and hedge fund investment groups at TR Capital. Bowie began her career with SSG Capital where she spent over eight years working across private equity mid- and back-office functions. Bowie holds a BA in Economics from Loughborough University in England.
Charles Wong, CPA
Chief Financial Officer
Charles Wong joined Ally Bridge Group in 2020 and is Chief Financial Officer for the private equity strategy. Before joining Ally Bridge Group, Charles spent over ten years in alternative asset management and financial services across various roles, including Chief Financial Officer at TR Capital, Vice President in the Finance team at CIitic PE and Financial Controller at DST. Charles began his career as an auditor at Deloitte in both New York and Hong Kong. Charles holds a BBA in Accounting and Finance from the Hong Kong University of Science and Technology and is a Certified Public Accountant.
Kerry Wong
Accounting Officer
Kerry Wong joined Ally Bridge Group in 2021 and is an Accounting Officer on the finance team. In this capacity, Kerry is responsible for corporate and general partner-related finance and operations. Before joining Ally Bridge Group, Kerry was an Accountant at DCP Capital. Kerry holds a BBS from Charles Sturt University in Australia.
Emma Yang
Director of Legal
Emma Yang joined Ally Bridge Group in 2022 and is Director of Legal for the private equity strategy. Before joining Ally Bridge Group, Emma was Head of Legal & Compliance for the Hong Kong office of C.M. Capital Advisors, the financial arm of Cha Group headquartered in Silicon Valley. Before that, Emma held various roles at international law firms including Mayer Brown JSM and King & Wood Mallesons. Emma holds an MCL from the University of Hong Kong and is a PRC qualified lawyer.
Public Equity
Investment Team
Hong Zheng, PhD
Research Analyst
Hong Zheng joined Ally Bridge Group in 2018 and is a Research Analyst for the public equity strategy focused on investments in biopharmaceuticals. Before joining Ally Bridge Group, Hong was a Senior Equity Research Associate at Royal Bank of Canada Capital Markets. Prior to that, Hong was a medicinal chemist at Ra Pharmaceuticals for three years where he led several drug discovery programs. Hong holds a BS in Chemistry from Fudan University and he received a PhD in Chemical Biology from Boston College.
Steven Plachtyna
Research Analyst
Steven Plachtyna joined Ally Bridge Group in 2020 and is a Research Analyst for the public equity strategy focused on investments in medical technology, tools and diagnostics. Before joining Ally Bridge Group, Steven was a Senior Research Associate at Citi Group and Bank of Montreal Capital Markets. Steven began his career at Medtronic. Steven holds a BS in Biomedical Engineering from the University of Connecticut, where he graduated cum laude, and he received a MEng in Biomedical Engineering and an MBA from Cornell University.
Tian Sun, PharmD
Research Analyst
Tian Sun joined Ally Bridge Group in 2021 and is a Research Analyst for the public equity strategy focused on investments in biopharmaceuticals. Tian is a pharmacist by training and has over five years of experience across retail and clinical pharmacy settings. Before joining Ally Bridge Group, Tian was an Equity Research Associate at Needham & Company. Tian began his career as an equity trader with Kershner Trading Group. Tian holds a PharmD from Rutgers University.
Business Team
Michael Bendetson
Head of Legal, Chief Compliance Officer
Michael Bendetson joined Ally Bridge Group in 2021 and is Head of Legal and Chief Compliance Officer for the public equity strategy. Before joining Ally Bridge Group, Michael was a Capital Markets Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP. Michael began his career as a Derivatives and Structured Products Associate for Davis Polk & Wardwell LLP. Michael holds a BA in Political Science from Tufts University, where he graduated magna cum laude, and he received a JD from the University of Michigan Law School.
Amy Herrup, CFA
Head of Business Development and Investor Relations
Amy Herrup joined Ally Bridge Group in 2021 and is Head of Business Development and Investor Relations. Before joining Ally Bridge Group, Amy was a Director in Client Solutions at Capstone Investment Advisors, LLC. Before that, Amy managed investor relations at Varadero Capital, L.P. Amy began her career at Goldman Sachs in the Securities Division. Amy holds a BA in Economics and Mathematical Methods in the Social Sciences from Northwestern University. She is a CFA charterholder.
Daniel Johnson, CPA
Chief Financial Officer
Daniel Johnson joined Ally Bridge Group in 2020 and is Chief Financial Officer for the public equity strategy. Before joining Ally Bridge Group, Daniel held various roles including Head of Finance and Administration at Elenion Capital, CFO/CCO at Castle Ridge Investment Management and COO/CFO/CCO at Trend Capital Management. Daniel began his career as a Senior Associate at Coopers & Lybrand before moving to Morgan Stanley, while also spending several years at Tiger Management. Daniel holds a BS in Accounting from the Pamplin College at Virginia Tech. He is a Certified Public Accountant.
Eric Kwong
Head of Operations
Eric Kwong joined Ally Bridge Group in 2021 and is Head of Operations for the public equity strategy. Before joining Ally Bridge Group, Eric was a Vice President on the Operations and Finance team for Jacobs Asset Management for eight years. Eric began his career at Citigroup as a hedge fund accountant before moving to Vastardis Capital Services as a middle office analyst. Eric holds a BBA in Finance from Baruch College.
Scientific Advisors
Tom Boone
Tom Boone has served as an independent consultant to Ally Bridge Group since 2014. Before co-founding REMD Biotherapeutics, Tom spent 28 years at Amgen and most recently was Global Head of Protein Science. Tom began his career at Amgen with the isolation and cDNA cloning of novel cytokines and growth factors. He later developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical application. Tom holds a BS in Genetics and an MS in Soil Science from the University of California, Davis and an MA in Microbiology from the University of California, Los Angeles.
Ryan Chang, MD, PhD
Ryan Chang has served as an independent consultant to Ally Bridge Group since 2014. Ryan is a trained physician scientist who practices internal medicine and hematology/oncology, and his scientific research focuses on developing nanoengineered materials as therapeutics for autoimmune, infectious and oncologic indications. Ryan holds a BS in Biomedical Engineering from the John Hopkins University and received an MD from the University of California, San Francisco (UCSF) School of Medicine as well as a PhD in Bioengineering from the UCSF and University of California, Berkley Joint Graduate Program.
Jennifer King, PhD
Jennifer King has served as an independent consultant to Ally Bridge Group since 2022. Before founding King BioConsulting in 2020, Jennifer worked at Intellia Therapeutics from 2015 to 2019 where she most recently was a Senior Vice President in Business Development. Before that, Jennifer was Senior Director of Business Development at Takeda Pharmaceutical Company Limited (formerly Shire Pharmaceuticals) from 2006 to 2015. Jennifer began her career at Millennium Pharmaceuticals where she held a variety of commercial roles. Jennifer holds a BS in Biology from the Massachusetts Institute of Technology, a PhD in Developmental Biology from the Stanford University School of Medicine, and an MBA from Northeastern University.
Luke Li, MD, PhD
Luke Li has served as an independent consultant to Ally Bridge Group since 2015. Most recently, Luke was Executive Director and Head of Biotherapeutic Technologies at Pfizer where he was actively involved in Pfizer’s global R&D investment and business development for five years. Before that, Luke spent 18 years at Amgen in pharmaceuticals R&D. Luke began his career in academia as a clinical professor at the Washington University School of Medicine. Luke holds an MD and MS in Pharmacology from Fujian Medical University.
Dayu Teng, PhD
Dayu Teng has served as an independent consultant to Ally Bridge Group since its establishment in 2013. Dayu is a post-doctoral researcher at the Institute of Biomedical Engineering at the University of California, San Diego (UCSD). Under the guidance of Dr. Shu Chien, founding chairman of the Institute of Biomedical Engineering at UCSD, Dayu co-founded a company that uses miniaturized high throughput live-cell screening technology to optimize the combinatorial drug therapies for cancer and infectious diseases. Dayu holds a BS, MS and PhD in Bioengineering from the UCSD.
We partner with companies across their entire lifecycle.
Diversified Investment in Global Healthcare Innovation.
Our life science investments span geography and sector, as we seek to identify those firms that hold the potential to transform healthcare for society in the years to come.
All
Private Equity
Aerin Medical
Aerin Medical is medical technology company focused on the ear, nose and throat market providing non-invasive solutions for the treatment of chronic nasal conditions.
Arbor Biotechnologies
Arbor Biotechnologies is a biotechnology company that aims to discover and develop the next generation of genetic medicines based on wholly owned genomic editors discovered from its machine learning/AI driven discovery platform.
BenevolentAI
BenevolentAI is a clinical-stage drug discovery company seeking to combine artificial intelligence and machine learning with science to decipher complex disease biology, generate new insights and discover more effective medicines. The company’s computational R&D platform spans each step of the drug discovery process, with a focus on novel disease targets discovery.
Ceribell
Ceribell is a medical device and artificial intelligence data analytics platform that deploys a cloud-linked, portable electroencephalogram (“EEG”) headband to facilitate rapid point-of-care diagnosis and treatment of life threatening neurological conditions.
CMR Surgical
CMR Surgical is a medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot. The company is committed to working with surgeons, surgical teams and hospital partners to provide a tool to redefine the surgical robotics market using technology that can improve surgical care as well as make robotic minimal access surgery universally accessible and affordable.
Elligo Health Research
Elligo Health Research uses electronic health records to help ensure that patients have access to clinical research as a possible care option. Powered by their “Goes Direct” approach and IntElligo Research Stack clinical technology, the company engages physicians and patients to help develop new pharmaceutical, biotechnology, medical device and diagnostic products.
Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage precision medicine company that targets the core drivers of multiple terminal diseases, including oncology and fibrosis. The Company seeks to combine advancements in technology with an evolving understanding of terminal diseases in order to develop best-in-class medicines with the potential to reverse the most severe health conditions.
Imperative Care
Imperative Care is a medical technology company focused on developing the next generation of solutions to address the needs for stroke patients. Together with its subsidiary, the company has two 510(k) cleared product platforms, as well as and a stroke technology and peripheral vascular disease development pipeline.
Insightec
Insightec is a medical device company creating the next generation of patient care by realizing the therapeutic power of focused ultrasound. The company’s Exablate platform focuses sound waves, safely guided by MRI, to treat patients with movement disorders.
Kestra Medical Technologies
Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects cardiac patients with its Wearable Cardioverter Defibrillator (ASSURE). The ASSURE system records and provides autonomous detection and defibrillation for ventricular arrhythmias and other clinically significant arrhythmias which may require clinical intervention. Kestra’s WCD is the only option that is designed specifically to meet the under-served needs of female cardiac patients.
LightForce
LightForce Orthodontics offers a fully personalized 3D printed braces system and digital treatment planning software. The Company is revolutionizing the orthodontic specialty through advanced manufacturing and technology. LightForce launched its first product to the orthodontic community in 2019 and now offers the only fully custom 7-to-7 braces system.
Luoxin Pharmaceuticals Group
Luoxin Pharmaceuticals Group is a healthcare conglomerate engaged in the research and development, manufacturing and sale of chemical medicine.
Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its implantable Restorative Neurostimulation™ system, ReActiv8®, for people with disabling mechanical chronic low back pain associated with multifidus muscle dysfunction who have failed pain medications and physical therapy, and are not candidates for spine surgery.
Mavrik Dental Systems
Mavrik Dental Systems focuses on developing proprietary technology for the in-office dental treatment market. The company’s Thera-Oral delivery platform and Thera-Smile whitening solution are automated systems that seek to help provide clinicians with efficient treatment plans.
MedAvail
MedAvail is a technology-enabled pharmacy organization that provides in-clinic pharmacy services through its proprietary robotic dispensing platform and home delivery operations to Medicare clinics. The company seeks to help physicians and patients to optimize drug adherence, resulting in better health outcomes.
Mission Bio
Mission Bio is a life science tools company focused on single cell genomics, proteomics and multi-omics solutions for oncology study and cell and gene therapy development.
ProfoundBio
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms.
Pulmonx
Pulmonx focuses on minimally invasive treatments for severe lung disease. The company’s platforms are designed to assess and treat patients with severe emphysema and chronic obstructive pulmonary disease who, despite medical management, are still symptomatic. Pulmonx completed its IPO on the Nasdaq stock market in October 2020.
Quantum Surgical
Quantum Surgical is a medical robotic company developing a solution dedicated to minimally invasive liver cancer treatment. The company aims to help physicians throughout a patient’s continuum of care, including pre-operative planning, intra-operative ablation treatment and post-operative care.
Rapid Micro Biosystems
Rapid Micro Biosystems is a provider of the fully automated, high-volume and secure Microbial Quality Control solution for pharmaceutical manufacturing (primary focus), food and beverage safety, personal care manufacturing, environmental water sector, industrial processing and diagnostics. The company completed its IPO on the Nasdaq stock market in July 2021.
RefleXion Medical
RefleXion Medical is a commercial stage company developing a biology-guided radiotherapy system, which allows for treatment of multiple tumors in the same treatment session in cancers that have metastasized.
Shoreline Biosciences
Shoreline Biosciences is a biotechnology company developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer and macrophage immunotherapies for the treatment of cancer.
Sonoma Biotherapeutics
Sonoma Biotherapeutics focuses on Treg cell therapies for autoimmune and degenerative diseases. Using genome editing and target-specific cell therapy, the company works to discover and develop disease modifying and curative therapies across the spectrum of Treg cell therapeutic capabilities.
Syapse
Syapse aims to use real-world evidence brought by Syapse Learning Health Network to improve the outcomes of cancer patients through improved precision medicine. Syapse and its partners are working towards a future where all cancer patients have access to the quality of care they need.
Transcarent
Transcarent is a digital health company focused on employee health benefits, aiming to improve the both the quality of care and reduce inefficiency in the existing healthcare system.
Vida Health
Vida Health is a digital management company focused on developing a proprietary technology platform that provides chronic disease, wellness and mental/behavioral health management solutions.
WuXi AppTec
WuXi AppTec provides a portfolio of R&D and manufacturing services that enable companies in the global pharmaceutical, biotechnology and medical device industries to advance discoveries and deliver treatments to patients. WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec completed its IPO on the Hong Kong stock exchange in December 2018.
WuXi Biologics
WuXi Biologics is a global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a one-stop service offering and strong value proposition to its global clients. WuXi Biologics completed its IPO on the Hong Kong stock exchange in June 2017.
We seek to leverage local relationships across the global marketplace.
Get in Touch.
Ally Bridge Group (NY) LLC
430 Park Avenue, 12th Floor
New York, New York 10022
Ally Bridge Group (HK) Limited
Gloucester Tower, The Landmark, 30th Floor
15 Queen’s Road Central, Hong Kong
For all investor inquiries, please reach out to investor.relations@ally-bridge.com.
Disclosure.
1.0 Terms of Use
Ally Bridge Group and its affiliates (together, “Ally Bridge”, “we”, or “us”) welcome you to our website (along with its accounts, pages and applications, collectively, the “Site”). By accessing, browsing and/or using the Site, you acknowledge that you have read and understand, and agree to be bound by the following terms and conditions of use and all disclaimers and terms and conditions that appear on the Site now, as well as the privacy policy of the Ally Bridge Site (the “Privacy Policy”, as set out in section 2 below, and together with the terms and conditions of use and all disclaimers and terms and conditions that appear on the Site, the “Terms”). This Site is offered to you conditioned on your acceptance without modification of the Terms contained herein. These Terms are a contract between you and Ally Bridge (the “Agreement”) and govern your visit to and use of the Site. This Agreement may be updated by us at any time. You should visit this page periodically to review the Agreement for changes. Your use of the Site, and your continued use of the Site after any such updates or modifications, constitutes your acceptance of the Terms. If you do not accept this Agreement, or if you cannot form a legally binding contract, you do not have permission to access, browse or use the Site and your sole and exclusive remedy is to discontinue using the Site.
1.1 Ownership of Materials on Site
All the material displayed on and/or accessible through the Site, including without limitation, software, text, graphics, charts, information, arrangements of information, images, articles, reports, presentations, screens, user documentation, user interfaces, related software and other material (the “Content”), is the property of Ally Bridge or others accessible via the Site and shall remain the exclusive property of Ally Bridge and its licensors, as the case may be. All Content is protected by international copyright and other laws. Nothing contained on the Site should be construed as granting, by implication, estoppel or otherwise, any license or right to use any Content without the written permission of Ally Bridge or such other party that may own the applicable Content. Nothing in this Agreement shall constitute a waiver of any trademark, copyright or other intellectual property rights. Ally Bridge reserves the right to enforce its intellectual property rights to the full extent of the law.
1.2 Restrictions on Use
The Site is for your personal education and non-commercial use. You may download or print out a hard copy of individual pages and/or sections of the Site, provided that you do not remove any copyright or other proprietary notices. Any downloading or otherwise copying from the Site will not transfer title to any software or material to you. You must not modify the paper or digital copies of any materials you have printed off or downloaded in any way, and you must not use any illustrations, photographs, video or audio sequences or any graphics separately from any accompanying text. You may not reproduce (in whole or in part), transmit (by electronic means or otherwise), modify, copy, distribute, publish, license, create derivative works from, link into, sell or use for any public or commercial purpose or in any way exploit the whole or any part of the Site without the prior written permission of Ally Bridge. We reserve all rights with respect to copyright and trademark ownership of all material on the Site. You may not use the Site in any way that is fraudulent, unlawful or violates any existing agreements you may have with Ally Bridge. Any unauthorized use of the Site or misuse of any information posted to the Site is strictly prohibited. You agree that you shall not place false or misleading information on the Site or upload any computer programs, including but not limited to viruses, Trojan horses or worms that may interfere with the proper operation of our sites. Ally Bridge may, in its sole discretion, terminate your use of the Site at any time. Ally Bridge reserves the right to change, suspend or discontinue all or any aspects of our sites at any time without prior notice.
1.3 Investment Disclaimer
This Site is for informational purposes only and should not be construed as a solicitation or offer, or recommendation to acquire or dispose of any investment or to engage in any other transaction. We do not provide investment, accounting, tax, legal or other specialist advice through the Site. If you would like investment, accounting, tax or legal advice, you should consult with your own financial advisors, accountants or attorneys regarding your individual circumstances and needs. You agree that Ally Bridge is not liable for any action you take or decision you make in reliance on any Content. Ally Bridge will not treat users of the Site as its partners, clients, customers or investors by virtue of their accessing the Site.
1.4 Performance Information
The information contained on or comments expressed on the Site may include certain prior indications of past investment performance. In considering such prior performance information, you should bear in mind that past performance is not indicative of future results and there can be no assurance that any investment will, or is likely to, achieve comparable results to those achieved in the past, or that significant losses will be avoided. Any projections, market outlooks or analyses, estimates and/or statements of opinions provided on the Site are forward-looking statements and are inherently uncertain and are based on a number of assumptions. Other events which were not taken into account may occur and may significantly affect investment returns or performance. You should carefully review information regarding any such analyses and underlying assumptions. Any reference to Assets Under Management or AUM used on the Site reflect the combined Assets Under Management of Ally Bridge investment advisors as of the specific time indicated. ANY PROJECTIONS, OUTLOOKS OR ASSUMPTIONS CONTAINED IN THE INFORMATION ON THIS WEBSITE SHOULD NOT BE CONSTRUED TO BE INDICATIVE OF THE ACTUAL EVENTS WHICH WILL OCCUR.
1.5 No Reliance
While we use reasonable efforts to obtain information from sources which we believe to be reliable, and to update the information on the Site, we make no representation that the information or opinions contained in the Site are accurate, reliable, updated or complete. The information and opinions contained in the Site are provided by us for personal use and informational purposes only and are subject to change without notice. Nothing contained on the Site constitutes investment, legal, tax or other advice nor is it to be relied on in making an investment or other decision.
1.6 Third-Party Links
We may provide links from the Site to websites operated by third parties who may or may not be affiliated with Ally Bridge. We have not reviewed unaffiliated sites linked to the Site, and we do not endorse, have any responsibility for or make any representations about, any other sites, including their products and services, content, communications, opinions and website use policies. We cannot and do not make any express or implied warranty about the accuracy, copyright compliance, legality, merchantability or any other aspect of the content of such links. The use of third party websites is entirely at your own risk. By accessing these links, you acknowledge that such other sites or locations are not under the control of Ally Bridge and that Ally Bridge does not endorse the content of such sites and locations, and you agree that Ally Bridge shall not be responsible for any information or additional links found at such site or location, or for your use of such information.
1.7 Local Regulatory Restrictions
This Site is not directed to any person in any jurisdiction where (for any reason) the publication or availability of this website is prohibited, and persons in respect of whom such prohibitions apply must not access this website. Those who choose to access the Site from other locations do so at their own initiative and are responsible for compliance with local laws.
Given the global nature of the internet, this Site may be accessed by visitors residing outside of the United States. Ally Bridge makes no representations or warranties that this Site is appropriate or available for use in countries outside of the United States, or that services discussed on this Site are available or appropriate for sale or use in all jurisdictions, or by all counterparties. Visitors who choose to access this Site from outside of the United States do so at their own initiative and are responsible for compliance with any and all local laws and regulations that may apply to such access. You may not use or export the information or materials in violation of U.S. export laws and regulations.
1.8 No warranty and limitations of liability
Ally Bridge, its affiliates and their respective officers, directors, managers, partners, members, shareholders, employees, affiliates and agents (collectively “Related Persons”) make no representations or warranties and specifically disclaim any and all warranties of any kind, express or implied, with respect to the Site and the Content, including any representations or warranties with respect to merchantability, fitness for a particular purpose, title, non-infringement, availability, security, accuracy, freedom from viruses or malware, completeness, timeliness, functionality, reliability, sequencing or speed of delivery. Your use of the Site and the Content is on an “as is” and “as available” basis. If you are not able to use or access the Site, or any websites linked to through the Site, Ally Bridge is not responsible for any problems that this causes.
In no event shall Ally Bridge, its affiliates or their Related Persons be liable to any party for any claims, liabilities, losses, costs or damages under any theory, including but not limited to any direct, indirect, punitive, special, incidental, or consequential damages arising out of in connection with any access, use (or inability to use) or distribution of the Site, or any Content therein, even if Ally Bridge or their related persons are advised of the possibility of such damages, losses or expenses. You acknowledge and agree that you may not bring a claim against Ally Bridge relating to your use of the Site after more than one year has passed since the event occurred that gave rise to the claim, while there is no such limitation on Ally Bridge’s right to bring claims against you. You acknowledge and agree that the disclaimers, including the warranty disclaimers, and the liability and remedy limitations in this Agreement are material terms of this Agreement and that they have been taken into account in the decision by Ally Bridge to provide the Site hereunder.
1.9 Governing Law
The Site is made available to you from the State of New York. The laws of New York will govern this Agreement (including any disputes concerning or related to this Agreement). The courts of New York have exclusive jurisdiction to settle any dispute, controversy or claim arising from or connected with this Agreement. Notwithstanding the foregoing, you expressly acknowledge and agree that Ally Bridge may seek injunctive or other appropriate relief in any court of competent jurisdiction and you consent to exclusive jurisdiction and venue in such courts. This Agreement is a personal agreement between you and Ally Bridge, and no one shall be a third party beneficiary to this Agreement. If any provision of this Agreement shall be unlawful, void, or for any reason unenforceable, then that provision shall be deemed severable from this Agreement, shall be enforced to the fullest extent allowed by law as to effect the intention of the parties, and shall not affect the validity and enforceability of any remaining provisions.
2.0 Privacy Policy
This privacy policy (the “Privacy Policy”) applies to your access and use of the Site and use of the Ally Bridge websites and/or other online programs, or the materials, software and content available in or through them (altogether, the “Site”). An important part of our commitment to you is our respect for your privacy as a user of the Site. This Privacy Policy seeks to help you understand whether and how we collect information about you when you visit the Site, and how we use such information.
Your visit to the Site is subject to this Privacy Policy and our Terms. By visiting, using and/or downloading any information available on the Site, you agree to this Privacy Policy and our Terms, which may be updated by us at any time, and consent to all actions that we take with respect to your data consistent with this Privacy Policy and our Terms. If you do not agree to this Privacy Policy or the Terms, you are instructed not to use this website. If we update our Privacy Policy, we will post the updated Privacy Policy here. Any such changes will be effective upon posting. You should visit this page periodically to review the Privacy Policy for changes. This privacy policy does not apply to information Ally Bridge collects offline or through email.
2.1 Information We Collect About You
We may make sensitive permissions requests and/or automatically collect information about your computer, tablet, mobile device or other electronic device when you visit our Site. This information may include your Internet Protocol (IP) address, Internet Service Provider (ISP), domain name, browser type, date and time of your request and information. We do not employ cookies. If you voluntarily submit information to our website, for example, in a request for general information or through the submission of a business proposal, we may record and use any personally identifiable information, financial information, authentication information, phonebook or contact data and sensitive device data for reasonable business purposes including, but not limited to, fulfilling your request. You acknowledge that you assume all responsibility related to the security, privacy and risks inherent in sending any content over the Internet.
2.2 Use of Information We Collect
Ally Bridge does not disclose any nonpublic personally identifiable information about its Site users to any nonaffiliated third party, except as set forth below.
We may use or disclose certain personally identifiable information we collect about you when you visit and browse the Site as part of our normal business operations, or to send you administrative communications either about your interactions with us or about features of the Site, including any future changes to this Privacy Policy. We may also use service providers to facilitate our services or platform functions on our behalf. These companies and individuals may have access to your personally identifiable information, as needed to perform their functions, but may not use it for another purpose. We will use or disclose personally identifiable information when we believe that such disclosures are required by law, regulation, legal process, subpoena, document request or governmental request, and we may disclose your communications and activities on the Site in response to requests by any government agency. Ally Bridge reserves the right to use any personally identifiable information in any manner permitted by law.
2.3 Protection of Information
We endeavor to protect your personally identifiable information. We use technical, administrative and physical methods to maintain the integrity and security of our databases, including firewalls. This website is not absolutely protected against unauthorized third parties. You acknowledge that any information provided through the Internet may be potentially accessed by unauthorized third parties. Although We will make reasonable efforts to protect the privacy of users of the Site, no guarantee can be made that unauthorized third parties will not access the information contained on the Site. You acknowledge that Ally Bridge is not responsible for notifying you that unauthorized third parties have gained such access or that any data has been otherwise compromised during transmission across computer networks or telecommunications facilities, including, but not limited to, the Internet. We will not be responsible or liable for any damages, losses or causes of action arising out of or in connection with the disclosure of your personally identifiable information.